Evidence map›Paper›PMID 30810749›Full record

ArticleJAMA surgery2019

Clinical Outcomes After Unilateral Adrenalectomy for Primary Aldosteronism.

Wessel M C M Vorselaars, Sjoerd Nell, Emily L Postma, Rasa Zarnegar, F Thurston Drake, Quan-Yang Duh, Stephanie D Talutis, David B McAneny, Catherine McManus, James A Lee and 27 more

Registry-linked trialOpen access · bronzeAbstract readMulticenter Study
In one paragraph

Article in JAMA surgery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04761354 (Characteristics Predicting Clinically Relevant Reduction of Hypertension Following Adrenalectomy for Primary Aldosteronism), which is not on this map. Cited by 55 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 3 pooled it
9.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04761354 completednot on this map

Characteristics Predicting Clinically Relevant Reduction of Hypertension Following Adrenalectomy for Primary Aldosteronism: a Multicenter Analysis

TypeobservationalSponsorUMC UtrechtRan2016 to 2017Enrolled514ConditionsPrimary Aldosteronism Due to Aldosterone Producing Adenoma, Primary Aldosteronism, Primary Aldosteronism Due to Conn AdenomaArmsUnilateral adrenalectomy
3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 3 syntheses or guidelines pooled it, 100 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Review
  8. Primary Aldosteronism Surgery Outcomes Under Current Blood Pressure Guidelines.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2026
    Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Bilateral adrenal artery embolization for the treatment of idiopathic hyperaldosteronism: A proof-of-principle single center study.Hypertension research : official journal of the Japanese Society of Hypertension · 2025
    Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. The left adrenal vein: An important direction for right adrenal venous sampling.Journal of clinical hypertension (Greenwich, Conn.) · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

37 authors at 18 institutions in 5 countries.

Wessel M C M VorselaarsDepartment of Surgical Oncology and Endocrine Surgery, University Medical Center Utrecht, Utrecht, the Netherlands.
Sjoerd NellDepartment of Surgical Oncology and Endocrine Surgery, University Medical Center Utrecht, Utrecht, the Netherlands.
Emily L PostmaDepartment of Surgical Oncology and Endocrine Surgery, University Medical Center Utrecht, Utrecht, the Netherlands.
Rasa ZarnegarDepartment of Endocrine and Minimally Invasive Surgery, Weill Cornell Medical College, New York, New York.
F Thurston DrakeDepartment of Surgery, University of California, San Francisco.
Quan-Yang DuhDepartment of Surgery, University of California, San Francisco.
Stephanie D TalutisDepartment of Surgery, Boston University School of Medicine, Boston, Massachusetts.
David B McAnenyDepartment of Surgery, Boston University School of Medicine, Boston, Massachusetts.
Catherine McManusDepartment of Endocrine Surgery, New York-Presbyterian-Columbia University, New York.
James A LeeDepartment of Endocrine Surgery, New York-Presbyterian-Columbia University, New York.
Scott B GrantDepartment of Surgery, University of Chicago Medical Center, Chicago, Illinois.
Raymon H GroganDepartment of Endocrine Surgery, Baylor St Luke's Medical Center, Houston, Texas.
Minerva A Romero ArenasDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston.
Nancy D PerrierDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston.
Benjamin J PeipertDepartment of Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Michael N MongelliDepartment of Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Tanya CastelinoSteinberg-Bernstein Centre for Minimally Invasive Surgery and Innovation, McGill University Health Centre, Montreal, Québec, Canada.
Elliot J MitmakerSteinberg-Bernstein Centre for Minimally Invasive Surgery and Innovation, McGill University Health Centre, Montreal, Québec, Canada.
David N ParenteDepartment of Surgery, University Health Network-Toronto General Hospital, Toronto, Ontario, Canada.
Jesse D PasternakDepartment of Surgery, University Health Network-Toronto General Hospital, Toronto, Ontario, Canada.
Anton F EngelsmanDepartment of Endocrine Surgery, Royal North Shore Hospital, Sydney, Australia.
Mark SywakDepartment of Endocrine Surgery, Royal North Shore Hospital, Sydney, Australia.
Gerardo D'AmatoDepartment of Endocrine and Metabolic Surgery, Policlinico Universitario A Gemelli-Università Cattolica del Sacro Cuore, Rome, Italy.
Marco RaffaelliDepartment of Endocrine and Metabolic Surgery, Policlinico Universitario A Gemelli-Università Cattolica del Sacro Cuore, Rome, Italy.
Valerie SchuermansDepartment of Surgery, Maastricht University Medical Center, Maastricht, the Netherlands.
Nicole D BouvyDepartment of Surgery, Maastricht University Medical Center, Maastricht, the Netherlands.
Hasan H EkerDepartment of Surgery, VU Medical Center, Amsterdam, the Netherlands.
H Jaap BonjerDepartment of Surgery, VU Medical Center, Amsterdam, the Netherlands.
N M Vaarzon MorelDepartment of Surgery, Academic Medical Center, Amsterdam, the Netherlands.
Els J M Nieveen van DijkumDepartment of Surgery, Academic Medical Center, Amsterdam, the Netherlands.
Otis M VrielinkDepartment of Surgery, University Medical Center Groningen, Groningen, the Netherlands.
Schelto KruijffDepartment of Surgery, University Medical Center Groningen, Groningen, the Netherlands.
Wilko SpieringDepartment of Vascular Medicine, University Medical Center Utrecht, Utrecht, the Netherlands.
Inne H M Borel RinkesDepartment of Surgical Oncology and Endocrine Surgery, University Medical Center Utrecht, Utrecht, the Netherlands.
Gerlof D ValkDepartment of Endocrine Oncology, University Medical Center Utrecht, Utrecht, the Netherlands.
Menno R VriensDepartment of Surgical Oncology and Endocrine Surgery, University Medical Center Utrecht, Utrecht, the Netherlands.
International CONNsortium study group
University Medical Center Utrecht · NLAcademic Medical Center · NLAmsterdam UMC Location VUmc · NLBoston University · USMaastricht University · NLMcGill University Health Centre · CANorthwestern University · USRoyal North Shore Hospital · AUThe University of Texas MD Anderson Cancer Center · USUniversità Cattolica del Sacro Cuore · ITUniversity Health Network · CAUniversity Medical Center Groningen · NLUniversity of California, San Francisco · USColumbia University · USCornell University · USSt. Luke's Hospital · USTexas Health Dallas · USUniversity of Chicago Medical Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

Importance: In addition to biochemical cure, clinical benefits after surgery for primary aldosteronism depend on the magnitude of decrease in blood pressure (BP) and use of antihypertensive medications with a subsequent decreased risk of cardiovascular and/or cerebrovascular morbidity and drug-induced adverse effects. Objective: To evaluate the change in BP and use of antihypertensive medications within an international cohort of patients who recently underwent surgery for primary aldosteronism. Design, Setting, and Participants: A cohort study was conducted across 16 referral medical centers in Europe, the United States, Canada, and Australia. Patients who underwent unilateral adrenalectomy for primary aldosteronism between January 2010 and December 2016 were included. Data analysis was performed from August 2017 to June 2018. Unilateral disease was confirmed using computed tomography, magnetic resonance imaging, and/or adrenal venous sampling. Patients with missing or incomplete preoperative or follow-up data regarding BP or corresponding number of antihypertensive medications were excluded. Main Outcomes and Measures: Clinical success was defined based on postoperative BP and number of antihypertensive medications. Cure was defined as normotension without antihypertensive medications, and clear improvement as normotension with lower or equal use of antihypertensive medications. In patients with preoperative normotensivity, improvement was defined as postoperative normotension with lower antihypertensive use. All other patients were stratified as no clear success because the benefits of surgery were less obvious, mainly owing to postoperative, persistent hypertension. Clinical outcomes were assessed at follow-up closest to 6 months after surgery. Results: On the basis of inclusion and exclusion criteria, a total of 435 patients (84.6%) from a cohort of 514 patients who underwent unilateral adrenalectomy were eligible. Of these patients, 186 (42.3%) were women; mean (SD) age at the time of surgery was 50.7 (11.4) years. Cure was achieved in 118 patients (27.1%), clear improvement in 135 (31.0%), and no clear success in 182 (41.8%). In the subgroup classified as no clear success, 166 patients (91.2%) had postoperative hypertension. However, within this subgroup, the mean (SD) systolic and diastolic BP decreased significantly by 9 (22) mm Hg (P < .001) and 3 (15) mm Hg (P = .04), respectively. Also, the number of antihypertensive medications used decreased from 3 (range, 0-7) to 2 (range, 0-6) (P < .001). Moreover, in 75 of 182 patients (41.2%) within this subgroup, the decrease in systolic BP was 10 mm Hg or greater. Conclusions and Relevance: In this study, for most patients, adrenalectomy was associated with a postoperative normotensive state and reduction of antihypertensive medications. Furthermore, a significant proportion of patients with postoperative, persistent hypertension may benefit from adrenalectomy given the observed clinically relevant and significant reduction of BP and antihypertensive medications.

Indexed as

AdrenalectomyBlood PressureAdultAgedAntihypertensive AgentsDiastoleFemaleHumansHyperaldosteronismHypertensionMaleMiddle AgedSystoleTreatment OutcomeAntihypertensive Agents

Identifiers

PMID30810749
PMCPMC6484800
OpenAlexW2917125411

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.